PMID- 34590150
OWN - NLM
STAT- MEDLINE
DCOM- 20220124
LR  - 20220124
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 24
IP  - 6
DP  - 2021 Dec
TI  - FOXP4 promotes laryngeal squamous cell carcinoma progression through directly 
      targeting LEF‑1.
LID - 831 [pii]
LID - 10.3892/mmr.2021.12471 [doi]
AB  - Forkhead box (FOX) proteins are multifaceted transcription factors that have been 
      shown to be involved in cell cycle progression, proliferation and metastasis. 
      FOXP4, a member of the FOX family, has been implicated in diverse biological 
      processes in tumor initiation and progression. However, the molecular mechanisms 
      of FOXP4 in laryngeal squamous cell carcinoma (LSCC) remain unknown. In the 
      present study, differentially expressed transcripts in transforming growth 
      factor‑beta‑treated TU177 cells were screened using microarrays and it was found 
      that FOXP4 was significantly upregulated. The high expression of FOXP4 was 
      detected in LSCC tissues and cells, and predicted poor prognosis. The role of 
      FOXP4 in laryngeal cancer cell proliferation, migration and invasion was 
      determined by gain‑ and loss‑of‑function assays. Besides, FOXP4 was demonstrated 
      to participate in the epithelial‑mesenchymal transition process at the mRNA and 
      protein levels. Mechanically, FOXP4 directly bound to the promoter of lymphoid 
      enhancer‑binding factor 1 and activated Wnt signaling pathway, which was 
      confirmed via chromatin immunoprecipitation and luciferase reporter assays. 
      Consequently, these findings provided novel mechanisms of FOXP4 in LSCC 
      progression, which may be considered as potential therapeutic and prognostic 
      targets for LSCC.
FAU - Shi, Jian
AU  - Shi J
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Wang, Jingtian
AU  - Wang J
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Cheng, Hongkun
AU  - Cheng H
AD  - Department of Otorhinolaryngology, The Third Hospital of Handan, Handan, Hebei 
      056001, P.R. China.
FAU - Liu, Shenghui
AU  - Liu S
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Hao, Xiaowei
AU  - Hao X
AD  - Department of Otorhinolaryngology, The People's Hospital of Cixian, Handan, Hebei 
      056500, P.R. China.
FAU - Lan, Lili
AU  - Lan L
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Wu, Gancun
AU  - Wu G
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Liu, Meng
AU  - Liu M
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
FAU - Zhao, Yan
AU  - Zhao Y
AD  - Department of Otolaryngology, Fourth Hospital of Hebei Medical University, 
      Shijiazhuang, Hebei 050011, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (FOXP4 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (LEF1 protein, human)
RN  - 0 (Lymphoid Enhancer-Binding Factor 1)
SB  - IM
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Forkhead Transcription Factors/*metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - Head and Neck Neoplasms/genetics/*metabolism
MH  - Humans
MH  - Lymphoid Enhancer-Binding Factor 1/*metabolism
MH  - Microarray Analysis
MH  - Squamous Cell Carcinoma of Head and Neck/genetics/*metabolism
MH  - Wnt Signaling Pathway
PMC - PMC8503739
OTO - NOTNLM
OT  - Wnt signaling pathway
OT  - epithelial‑mesenchymal transition
OT  - forkhead box P4
OT  - laryngeal squamous cell carcinoma
OT  - lymphoid enhancer‑binding factor 1
OT  - transforming growth factor‑beta
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/01 06:00
MHDA- 2022/01/27 06:00
PMCR- 2021/09/28
CRDT- 2021/09/30 07:25
PHST- 2021/06/13 00:00 [received]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/09/30 07:25 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2022/01/27 06:00 [medline]
PHST- 2021/09/28 00:00 [pmc-release]
AID - 831 [pii]
AID - MMR-0-0-12471 [pii]
AID - 10.3892/mmr.2021.12471 [doi]
PST - ppublish
SO  - Mol Med Rep. 2021 Dec;24(6):831. doi: 10.3892/mmr.2021.12471. Epub 2021 Sep 30.